Innovent Biologics and Pfizer have entered a global licensing and collaboration agreement to research and develop 12 early-stage cancer medicines, including antibody-drug conjugates and multi-specific antibodies. Innovent will lead initial development through Phase 1, after which Pfizer will take over global development. The companies will co-develop four programs and share costs and profits in the U.S. and Europe, with Innovent retaining rights in Greater China. The deal includes a $650 million upfront payment to Innovent and potential milestone payments up to $9.85 billion, totaling up to $10.5 billion. This partnership aims to accelerate bringing innovative cancer therapies to patients worldwide.
Innovent Biologics has entered a $10.5 billion partnership with Pfizer to co-develop and co-commercialize a portfolio of 12 early-stage cancer medicines, focusing on antibody-drug conjugates. Innovent will share costs and profits with Pfizer in the U...
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...
The iShares Select Dividend ETF (DVY) provides a reliable income stream with a trailing yield of about 3.5%, sourced from dividends of roughly 100 U.S. companies known for stable payouts. Its portfolio focuses on defensive sectors like utilities, fin...
